Peptide profile · Weight Management
Retatrutide
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team
Dose timeline
2 mg
Weeks 1-4 (then escalate 2 mg every 4 weeks)
4-8 mg
Maintenance after titration
12 mg
Maintenance (highest studied)
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
Molecular weight
4731 g/mol
Evidence level
Moderate human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C221H342N46O68
Primary benefits
Delivers the highest weight loss ever recorded in Phase 2 obesity trials—up to 24% body weight reduction at the 12mg dose
Dramatically improves blood sugar, HbA1c, and metabolic markers through triple receptor activation
Powerfully reduces hunger and cravings through multiple brain pathways, making dietary changes feel natural
Eli Lilly and Company
Amino acid sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Gln-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys(C20 diacid)-NH202 · Dosing
How much do I take?
2 mg, titrated to 4-8 mg · once weekly
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Pick any consistent day each week—what matters most is doing it the same day each week. Many people choose weekend mornings so any initial nausea happens when they can rest.
With food?
Inject regardless of food timing. However, eating slowly and avoiding large, fatty meals helps minimize nausea. Many users find eating smaller, more frequent meals works better on this medication.
If stacking
Do not combine with other GLP-1 agonists like semaglutide or tirzepatide—retatrutide already hits all three receptors [2]. Metformin is safe and often beneficial to continue [6].
＋ Increase if
- +You've been on current dose for 4+ weeks with good tolerance
- +Weight loss has plateaued and you're below target
- +GI side effects have resolved or become minimal
- +Your healthcare provider recommends escalation
－ Decrease if
- −Nausea or vomiting is persistent and interfering with daily life
- −You're losing weight too rapidly (more than 3 lbs/week consistently)
- −GI side effects don't improve after 2-3 weeks on current dose
- −You experience hypoglycemia symptoms
✓ Signs of right dose
- ✓Steady weight loss of 1-2 lbs per week
- ✓Reduced appetite without severe nausea
- ✓Improved energy levels
- ✓Blood sugar levels stabilizing (if diabetic)
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for significant weight loss & type 2 diabetes management
Best for
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Retatrutide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Subcutaneous injection
Reconstitution — what you need
Example
Most clinical trials used pre-filled delivery systems. If using research vials, typical concentration allows direct withdrawal of the prescribed dose. Example: 5mg/mL concentration—for a 4mg dose, draw 0.8mL.
For research purposes with a 5mg/mL solution: 1mg dose = 0.2mL (20 units on insulin syringe), 4mg dose = 0.8mL (80 units), 8mg dose = 1.6mL (may require two injections), 12mg dose = 2.4mL (multiple injection sites needed).
Route
Subcutaneous injection (just under the skin)—the same easy technique used for insulin
Best sites
Technique
- 01Wash hands thoroughly with soap and water
- 02Clean the injection site with an alcohol swab and let it dry completely
- 03Pinch a fold of skin at the injection site
- 04Insert the needle at a 45-90 degree angle (90 degrees if you have adequate subcutaneous tissue)
- 05Inject the medication slowly over 5-10 seconds
- 06Remove the needle and apply gentle pressure—don't rub
Storage · before reconstitution
Keep retatrutide refrigerated at 36-46°F (2-8°C). Protect from light by keeping in original packaging. Never freeze the medication. Can tolerate brief periods at room temperature (up to 86°F/30°C) for transport.
Storage · after reconstitution
Once prepared for use, store refrigerated at 36-46°F (2-8°C). Do not freeze reconstituted solution. Keep away from direct light. Use within 28 days of first use.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 3 serious
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Current safety data comes from Phase 1 and Phase 2 trials conducted by Eli Lilly. Multiple Phase 3 trials are currently underway to establish long-term safety in larger populations. As a research compound not yet FDA approved, the full safety profile is still being established.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or persistent abdominal pain (possible pancreatitis)—seek emergency care
- ×Signs of allergic reaction: rash, swelling, difficulty breathing
- ×Persistent severe nausea or vomiting that doesn't improve with dose reduction
- ×Symptoms of gallbladder problems (right upper abdominal pain)
- ×Symptoms of severe hypoglycemia that recur despite medication adjustments
- ×Any concerning mental health changes
Retatrutide is an investigational medication currently in clinical trials. It is not FDA approved. Any use should be under the supervision of a qualified healthcare provider. Never start, stop, or change your dose without medical guidance.
With other peptides
- !Semaglutide — Do NOT combine. Both target the GLP-1 receptor—using them together provides no additional benefit and increases side effects.
- !Tirzepatide — Do NOT combine. Retatrutide already hits both GIP and GLP-1 receptors that tirzepatide targets, plus glucagon.
- ✓BPC-157 — Limited interaction data. Theoretically safe as they work through different mechanisms, but use caution.
- ✓Ipamorelin/CJC-1295 — No direct interaction known. Some users stack for body composition, but data is limited.
With medications
- !Insulin — High interaction risk. Retatrutide dramatically lowers blood sugar—insulin doses typically need significant reduction (20-50%) to prevent hypoglycemia.
- !Sulfonylureas (glipizide, glyburide) — Increased hypoglycemia risk. These drugs also stimulate insulin release. Dose reduction usually needed.
- ✓Metformin — Safe and often beneficial combination. Metformin works through different mechanisms and complements retatrutide well.
- ✓SGLT2 inhibitors (empagliflozin, dapagliflozin) — Generally safe combination used in clinical trials. Both promote weight loss through different mechanisms.
- ✓Oral contraceptives — Slowed GI transit may affect absorption. Consider using backup contraception or switch to non-oral methods.
- ✓Levothyroxine — Take thyroid medication at least 30-60 minutes before retatrutide or 4 hours after. GI slowing may affect absorption.
With supplements
- ✓Vitamin B12 — GLP-1 agonists may reduce B12 absorption over time. Consider supplementation, especially long-term.
- ✓Protein supplements — Safe and often helpful to maintain adequate protein intake while eating less overall.
- ✓Fiber supplements — Safe but start slowly. Can help with constipation but may worsen early GI symptoms if added too quickly.
- ✓Multivitamins — Safe and recommended. When eating less food, ensuring micronutrient adequacy is important.
06 · Effectiveness
How do I know it's working?
Moderate human trials · first signs weeks 1-4
Evidence level
Moderate human trials
(Phase 1-2)
How it works
Think of retatrutide as a master key that unlocks three different locks in your body's weight regulation system. First, it activates GLP-1 receptors in your brain to reduce hunger and help you feel full faster. Second, it hits GIP receptors which help your body handle nutrients better and may improve how fat cells work. Third—and this is what makes retatrutide special—it activates glucagon receptors, which tells your body to burn more fat for energy [2]. It's like having three different weight-loss helpers working together at once, which is why the results are so dramatic.
Retatrutide (LY3437943) is a single-molecule triagonist with balanced agonism at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors [2]. The GLP-1 receptor activation suppresses appetite through hypothalamic signaling, delays gastric emptying, and enhances glucose-dependent insulin secretion. GIP receptor agonism contributes to incretin-mediated insulin secretion and may improve adipose tissue function. The glucagon receptor component is the distinguishing feature—it increases hepatic glucose production and lipolysis, promotes fatty acid oxidation, and increases energy expenditure through thermogenesis [2]. The C20 fatty diacid conjugation to lysine-17 enables albumin binding, extending half-life to approximately 6 days for once-weekly dosing. Compared to endogenous ligands, retatrutide is approximately 0.3x as potent at the glucagon receptor and 0.4x at GLP-1 receptor, but roughly 8.9x more potent at the GIP receptor, creating a unique pharmacological profile that maximizes metabolic benefits while managing side effects.
What to expect
Weeks 1-4
What you might notice
- •Reduced appetite—you may feel full faster than usual
- •Some nausea, especially after larger meals
- •Possible early weight loss (3-5 lbs in the first month)
- •Changes in food preferences—some cravings may diminish
- •Mild GI symptoms as your body adjusts
What's normal
- •Mild to moderate nausea that improves between doses
- •Eating smaller portions without feeling deprived
- •Some trial and error finding foods that sit well
What's next
- →Stay consistent with your weekly injection schedule
- →Prepare for potential dose increase after 4 weeks
- →Focus on protein-rich, nutrient-dense foods
Weeks 5-12
What you might notice
- •More significant weight loss becoming visible
- •GI side effects generally improving
- •Improved blood sugar levels if diabetic
- •Sustained appetite control between doses
- •Increased energy as you lose weight
What's normal
- •Steady weight loss of 1-2 lbs per week
- •Needing smaller meals to feel satisfied
- •Side effects diminishing as your body adapts
What's next
- →Continue gradual dose increases as tolerated
- →Incorporate regular physical activity if not already
- →Track your progress—weight, measurements, how clothes fit
Weeks 13-24
What you might notice
- •Substantial weight loss—trials showed 17-18% average at 24 weeks on higher doses [1]
- •Significant improvements in metabolic markers
- •Better fitting clothes, visible body changes
- •Improved mobility and physical comfort
- •Blood sugar and blood pressure often improving
What's normal
- •Continued weight loss though rate may slow slightly
- •Feeling adapted to the medication
- •New eating habits becoming routine
What's next
- →Discuss long-term plans with your healthcare provider
- →Continue healthy lifestyle habits to maintain results
- →Monitor for any new or worsening side effects
Weeks 24-48+
What you might notice
What's normal
- •Weight loss gradually plateauing as you approach new set point
- •Feeling like this is your 'new normal' for eating
- •Long-term side effects minimal for most users
What's next
- →Work with your provider on maintenance strategy
- →Maintain healthy lifestyle habits established during treatment
- →Consider long-term medication plans as Phase 3 data emerges
Signs it's working · Weight Loss Indicators
- ✓Scale weight decreasing consistently over weeks
- ✓Clothes fitting more loosely
- ✓Visible changes in face, neck, and waist
- ✓Reduced waist circumference
- ✓Lower body mass index (BMI)
Signs it's working · Appetite and Eating Changes
- ✓Feeling full faster during meals
- ✓Reduced food cravings, especially for high-calorie foods
- ✓Going longer between meals without hunger
- ✓Smaller portions feeling satisfying
- ✓Less mental preoccupation with food
Signs it's working · Metabolic Improvements
- ✓Lower fasting blood sugar levels
- ✓Improved HbA1c (if diabetic)
- ✓Better cholesterol numbers on blood tests
- ✓Reduced blood pressure
- ✓Lower liver enzymes (fatty liver improvement)
Signs it's working · Quality of Life
- ✓Increased energy and less fatigue
- ✓Improved mobility and easier physical activity
- ✓Better sleep quality
- ✓Increased confidence and mood improvement
- ✓Reduction in weight-related joint pain
Not seeing results? Common reasons
- •Dose too low—retatrutide shows strong dose-dependent effects; significant weight loss typically requires 4mg+ doses [1][3]
- •Not enough time—real transformation takes 24-48 weeks; don't expect dramatic results in the first month
- •Eating through the appetite suppression—some people need to consciously honor the reduced hunger rather than eating out of habit
- •Poor injection technique—ensure full dose is actually administered subcutaneously
- •Missing doses—weekly dosing requires consistency; missed doses reduce effectiveness
- •Underlying metabolic conditions not addressed—thyroid issues or other hormonal imbalances may need separate treatment
Key research
07 · Clinical trials
Tested in people
43 registered studies, 2 still enrolling.
43
registered studies
2
recruiting now
14
phase 3 or 4
6
with published results
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 29,131 people took part in the studies that actually administered Retatrutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
N1T-MC-MALO
Eli Lilly & Co.
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Hudson Biotech
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Retatrutide is named as an intervention; studies that only mention it in passing are not.
08 · Questions
Frequently asked
How is retatrutide different from tirzepatide (Mounjaro/Zepbound)?+
Tirzepatide is a dual agonist hitting GIP and GLP-1 receptors. Retatrutide adds a third target—the glucagon receptor—which appears to increase fat burning and energy expenditure beyond what dual agonists achieve [2]. This triple action may explain why retatrutide produced higher weight loss (24%) compared to tirzepatide (21%) in their respective trials [1][10].
When will retatrutide be available?+
Retatrutide is currently in Phase 3 clinical trials [11]. If trials are successful and FDA approves it, the earliest it could potentially be available is 2026-2027. Multiple trials are ongoing for obesity, type 2 diabetes, fatty liver disease, and other conditions.
Can I use retatrutide with other weight loss medications?+
You should NOT combine retatrutide with other GLP-1 based medications like semaglutide or tirzepatide—retatrutide already covers those receptor targets [2]. However, metformin and SGLT2 inhibitors were safely used alongside retatrutide in clinical trials.
What happens to the weight if I stop taking it?+
Based on data from similar medications, some weight regain is expected after stopping [12]. However, maintaining healthy lifestyle changes developed during treatment can help preserve results. Long-term maintenance strategies are still being studied.
Is the nausea really that bad?+
Nausea is the most common side effect, affecting about 25-40% of users depending on dose. However, it's usually mild to moderate, improves with time, and is largely manageable by starting with low doses and increasing gradually. Most people find it tolerable given the significant weight loss benefits.
Will retatrutide affect my thyroid?+
GLP-1 class medications carry warnings about thyroid C-cell tumors based on rodent studies, but this hasn't been observed in humans [13]. However, people with personal or family history of medullary thyroid carcinoma should not use retatrutide as a precaution.
Do I need to diet and exercise too?+
While retatrutide produces significant weight loss even without intensive lifestyle intervention, combining it with healthy eating and regular physical activity maximizes results and helps maintain weight loss long-term. The medication makes dietary changes easier by reducing hunger and cravings.
How does retatrutide compare to semaglutide (Ozempic/Wegovy)?+
Semaglutide targets only the GLP-1 receptor and produces about 15-17% weight loss [12][14]. Retatrutide's triple mechanism delivers approximately 24% weight loss at the highest dose—about 40% more weight loss [1]. However, semaglutide is FDA approved and available now, while retatrutide is still investigational.